| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7662858 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(5 years from now) | |
| US8110606 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(5 years from now) | |
| US7884095 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(5 years from now) | |
| US7939518 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(5 years from now) | |
| US8623920 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(5 years from now) | |
| US9561200 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(5 years from now) | |
Zipsor is owned by Assertio.
Zipsor contains Diclofenac Potassium.
Zipsor has a total of 6 drug patents out of which 0 drug patents have expired.
Zipsor was authorised for market use on 16 June, 2009.
Zipsor is available in capsule;oral dosage forms.
Zipsor can be used as diclofenac potassium for relief of mild to moderate acute pain, nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain.
The generics of Zipsor are possible to be released after 24 February, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 25, 2024 |
Drugs and Companies using DICLOFENAC POTASSIUM ingredient
Market Authorisation Date: 16 June, 2009
Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain
Dosage: CAPSULE;ORAL
ZIPSOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic